Compare PPL Corporation Common Stock (PPL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPL Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? PPL Corporation Common Stock trades at $34.75 (market cap $26.06B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: PPL Corporation Common Stock is far larger — about 6.9× Tango Therapeutics Inc.'s market cap, and PPL Corporation Common Stock pays a 3.29% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPL Corporation Common Stock for 5 Days and Tango Therapeutics Inc. for 0 Days on average.
| PPL | TNGX | |
|---|---|---|
Market Cap | $26.06B | $3.75B |
Volume | 5,432,693 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $39.81 | $32.90 |
52-Week Low | $31.97 | $7.50 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $46.05B | $2.77B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPL Corporation trades at $34.63, up 0.84% with a bullish technical outlook supported by moving averages. The utility company shows solid fundamentals with $9.04B revenue, 13.47% net margin, and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $39.45 price target, representing 14% upside potential from current levels. Recent news highlights PPL's $23B infrastructure investment plan and focus on meeting rising electricity demand through strategic capacity expansion.
PPL presents a compelling investment case with strong analyst support, dividend growth potential, and strategic positioning in the growing utility sector. Key risks include execution challenges from the massive capital expenditure program, regulatory hurdles, and competitive pressures. The stock's current valuation at 20.49 P/E appears reasonable given the company's growth trajectory and defensive characteristics in the utility space.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PPL Corporation Common Stock
PPL Corporation is a regulated utility holding company. Through its subsidiaries, it generates, transmits, distributes, and sells electricity and natural gas in Kentucky, Pennsylvania, and Rhode Island.
Read more on PPL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
